Back to search
FDAFDA · Food and drugs·Recall number D-0213-2024

Eprontia (topiramate) oral solution, 25 mg/mL, 473 mL Bottle, Rx only, Manufactured for: Azurity Pharmaceuticals, Woburn, MA 01801, NDC 52652-9001-1

Published January 10, 2024 · Recall initiated: December 8, 2023

Summary

FDA records drug Class III recall D-0213-2024, published January 10, 2024 and initiated December 8, 2023. Recalling firm: Azurity Pharmaceuticals, Inc.; Status: Terminated; Reported quantity: 2,220 bottles; Lot: Lot #: MB22020B, Exp 12/27/2023. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Impurities/Degradation Specifications: Out of specification Impurity C (4,5-desisopropylidene topiramate) result observed during routine stability testing at 18 months.

What to do

Voluntary: Firm initiated · Letter

Get an email if EPRONTIA has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
EPRONTIA
Manufacturer
Azurity Pharmaceuticals, Inc.
Distributor
USA nationwide.
Lot
Lot #: MB22020B, Exp 12/27/2023
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Eprontia (topiramate) oral solution, 25 mg/mL, 473 mL Bottle, Rx only, Manufactured for: Azurity Pharmaceuticals, Woburn, MA 01801, NDC 52652-9001-1 recalled?

Yes. FDA published recall D-0213-2024 on January 10, 2024. Reported hazard: Failed Impurities/Degradation Specifications: Out of specification Impurity C (4,5-desisopropylidene topiramate) result observed during routine stability testing at 18 months.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: EPRONTIA.